Sign In
Buy FLUX
$0.790
-0.0149 (-1.85%)
At Close: Jun 23, 2026
What are the benefits of LiFeP04 for electric forklifts?
12:37am, Tuesday, 02'nd Jun 2020
The aim of CHASE Technologies is to convert 50% of the current electric forklift market from lead-acid to lithium iron phosphate batteries within 5 years.
Organ Transplant Rejection Medications Market, 2017-2019 & 2020-2027 - ResearchAndMarkets.com
12:00am, Monday, 01'st Jun 2020
The
Dalitality: Labour laws and the muffled voices of 93%
10:20am, Sunday, 31'st May 2020
Labour laws are a conglomeration of close to 250 Central and state laws that grant protection to the labourer by regulating fair wages, conditions of work, overtime, leave, and social securities throu
More parts for electric vehicles to be made in India: ION Energy
05:48pm, Saturday, 30'th May 2020
The local supply chain for all critical parts of EVs a must: Akhil Aryan of ION Energy. For the record, ION Energy is a tier-1 supplier to manufacturers like Bajaj Auto and TVS Motor Company, the two
Battlefield Management System: A critical technology for Indo-China border
05:11pm, Saturday, 30'th May 2020
For decades there has been no exchange of fire in hostilities between the troops of the Indian Army and the People’s Liberation Army (PLA) due to the restraint exercised by both.
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trials -
12:19pm, Saturday, 30'th May 2020
Competition heats up in BCMA CAR-T therapy as J&J, BMS update multiple myeloma trials at ASCO20
Small-cap round-up: featuring Helical, Braemar, Medica and more - Master Investor
10:24am, Friday, 29'th May 2020
In this weekly summary, Mark Watson-Mitchell updates his readers on previous company profiles and other news of interest from the exciting world of small cap stocks…
Montreal’s Repare Therapeutics files for $100-million IPO on Nasdaq, first new issue by Canadian biotech in a year
11:24pm, Thursday, 28'th May 2020
If successful, it would be the first Canadian biotech IPO on the premier exchange for early stage drug developers since Milestone Pharma
Bristol Myers jumps into synthetic lethality with $65M Repare deal
02:24pm, Thursday, 28'th May 2020
As it ushers the CAR-T treatments it picked up from Celgene toward approval, Bristol Myers Squibb is already working on its next chapter. It’s teaming up with Repare Therapeutics to find new synthet
BMS wins another lung cancer approval for its Opdivo+Yervoy combo -
06:57am, Thursday, 28'th May 2020
Bristol-Myers Squibb has won a second first-line lung cancer approval from the FDA for its Opdivo and Yervoy combination.
Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential
12:00am, Wednesday, 27'th May 2020
Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have...
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb
12:00am, Tuesday, 26'th May 2020
Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vu
States compete to bring in sweeping changes to labour laws, ‘competition to attract capital’, say analysts
02:43am, Sunday, 24'th May 2020
A blanket suspension of labour laws, as has been in the case of UP, however, may not find favour, with the Centre leaning towards putting caveats in order to protect the rights of bonded labour, child
